English

Therapix Biosciences Ltd.

EDGAR

SPRC Report (type unavailable) · filed 2026-10-07

Annual consolidated revenue for 2025: about USD 856K, using the latest reported figures. The previous period, 2024, was about USD 1.306M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

856 thousand USD

2025 · USD

Exact inputs and evidence

Revenue: 856000 USD Source

Operating margin

-978.27%

2025 · %

Exact inputs and evidence

Operating Income: -8374000 USD Source
Revenue: 856000 USD Source

Operating cash flow

-4.14 million USD

2025 · USD

Exact inputs and evidence

Operating Cash Flow: -4137000 USD Source

Free cash flow

-7.93 million USD

2022 · USD

Exact inputs and evidence

Operating Cash Flow: -7917000 USD Source
Capital Expenditure: 8000 USD Source

Cash and cash equivalents: Not available
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-07.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2022-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: 2 of 11 periods available· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-34.5%

Prior period

USD 1.31 million

2024-01-01 – 2024-12-31
Current period

USD 856,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

856000 − 1306000 = -450000 USD

1306000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
856000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Therapix Biosciences Ltd. · 2025-12-31 Therapix Biosciences Ltd. (edgar:1611746) Year-over-year change in Revenue: -450000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 856000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#967090 Filing: 000121390026091427 Input fundies:Revenue: 1306000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#986101 Filing: 000121390026091427
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 5.9 million

Prior period

−USD 6.28 million

2024-01-01 – 2024-12-31
Current period

−USD 12.18 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-12179000 − -6284000 = -5895000 USD

-6284000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-12179000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Therapix Biosciences Ltd. · 2025-12-31 Therapix Biosciences Ltd. (edgar:1611746) Year-over-year change in Net income: -5895000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -12179000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#205221 Filing: 000121390026091427 Input fundies:NetIncome: -6284000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#205573 Filing: 000121390026091427
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 967,000

Prior period

−USD 5.1 million

2024-01-01 – 2024-12-31
Current period

−USD 4.14 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-4137000 − -5104000 = 967000 USD

-5104000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-4137000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Therapix Biosciences Ltd. · 2025-12-31 Therapix Biosciences Ltd. (edgar:1611746) Year-over-year change in Operating cash flow: 967000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -4137000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#412770 Filing: 000121390026091427 Input fundies:OperatingCashFlow: -5104000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#358373 Filing: 000121390026091427
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 856,000 100% of revenue
Operating costs Derived USD 9.23 million 1,078% of revenue
Operating income −USD 8.37 million −978% of revenue
Tax, interest and other Derived USD 3.81 million 445% of revenue
Net income −USD 12.18 million −1,423% of revenue

Cash

Operating cash flow −USD 4.14 million −483% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2022 Operating loss: operating costs were 715% of revenue.
2023 Operating loss: operating costs were 337% of revenue.
2024 Operating loss: operating costs were 660% of revenue.
2025 Operating loss: operating costs were 1,078% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2022 2022-01-01 – 2022-12-31	1347000	9634000 Derived	-8287000	-5695000 Derived	-2592000	-7925000 Derived	Source 2022-01-01 – 2022-12-31: 1347000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -8287000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -2592000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -7917000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 8000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	2879000	9694000 Derived	-6815000	-1693000 Derived	-5122000	Unavailable	Source 2023-01-01 – 2023-12-31: 2879000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -6815000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -5122000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -5887000 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	1306000	8622000 Derived	-7316000	-1032000 Derived	-6284000	Unavailable	Source 2024-01-01 – 2024-12-31: 1306000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -7316000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -6284000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -5104000 USD Inspect Operating Cash Flow Open source
2025 2025-01-01 – 2025-12-31	856000	9230000 Derived	-8374000	3805000 Derived	-12179000	Unavailable	Source 2025-01-01 – 2025-12-31: 856000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -8374000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -12179000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -4137000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 856K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Revenue	1347000	Revenue: 1347000 Open source
20232023-12-31	Revenue	2879000	Revenue: 2879000 Open source
20242024-12-31	Revenue	1306000	Revenue: 1306000 Open source
20252025-12-31	Revenue	856000	Revenue: 856000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-34.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Year over year	No prior comparable period	Revenue: 1347000 Open source
20232023-12-31	Year over year	113.7%	Revenue: 2879000 Open source Revenue: 1347000 Open source
20242024-12-31	Year over year	-54.6%	Revenue: 1306000 Open source Revenue: 2879000 Open source
20252025-12-31	Year over year	-34.5%	Revenue: 856000 Open source Revenue: 1306000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -978.3% 2025

Net margin -1,422.8% 2025

Free cash flow margin -588.3% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Operating margin	-615.2%	Operating Income: -8287000 Open source Revenue: 1347000 Open source
20232023-12-31	Operating margin	-236.7%	Operating Income: -6815000 Open source Revenue: 2879000 Open source
20242024-12-31	Operating margin	-560.2%	Operating Income: -7316000 Open source Revenue: 1306000 Open source
20252025-12-31	Operating margin	-978.3%	Operating Income: -8374000 Open source Revenue: 856000 Open source
20222022-12-31	Net margin	-192.4%	Net Income: -2592000 Open source Revenue: 1347000 Open source
20232023-12-31	Net margin	-177.9%	Net Income: -5122000 Open source Revenue: 2879000 Open source
20242024-12-31	Net margin	-481.2%	Net Income: -6284000 Open source Revenue: 1306000 Open source
20252025-12-31	Net margin	-1,422.8%	Net Income: -12179000 Open source Revenue: 856000 Open source
20222022-12-31	Free cash flow margin	-588.3%	Revenue: 1347000 Open source Operating Cash Flow: -7917000 Open source Capital Expenditure: 8000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 2879000 Open source Operating Cash Flow: -5887000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 1306000 Open source Operating Cash Flow: -5104000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 856000 Open source Operating Cash Flow: -4137000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -4.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Operating cash flow	-7917000	Operating Cash Flow: -7917000 Open source
20232023-12-31	Operating cash flow	-5887000	Operating Cash Flow: -5887000 Open source
20242024-12-31	Operating cash flow	-5104000	Operating Cash Flow: -5104000 Open source
20252025-12-31	Operating cash flow	-4137000	Operating Cash Flow: -4137000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -7.9M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Free cash flow	-7925000	Operating Cash Flow: -7917000 Open source Capital Expenditure: 8000 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -5887000 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -5104000 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -4137000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2022-12-31	Liabilities / assets	Not reported	No source recorded
2023-12-31	Liabilities / assets	Not reported	No source recorded
20242024-12-31	Liabilities / assets	Not reported	Total Liabilities: 1408000 Open source
20252025-12-31	Liabilities / assets	Not reported	Total Liabilities: 2475000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2022-12-31	Current assets / current liabilities	Not reported	No source recorded
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	USD 1.99 million Exact value Exact value: 1993000 USD 2016-01-01 – 2016-12-31: 1993000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2016-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: 1993000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: 1993000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390019008868/trpx-20181231.xml#1211348 Filing: 000121390019008868 The citation records this snapshot. The page link may show a newer release later.	−USD 1.47 million Exact value Exact value: -1474000 USD 2016-01-01 – 2016-12-31: -1474000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2016-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -1474000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1474000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390019008868/trpx-20181231.xml#162316 Filing: 000121390019008868 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2016-01-01 – 2016-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Therapix Biosciences Ltd. · 2016-12-31 Therapix Biosciences Ltd. (edgar:1611746) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390019008868/trpx-20181231.xml#163503 Filing: 000121390019008868 The citation records this snapshot. The page link may show a newer release later.	−USD 1.48 million Calculation and evidence -1474000 − 4000 USD Exact free cash flow: -1478000 USD 2016-01-01 – 2016-12-31: -1474000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Therapix Biosciences Ltd. · 2016-12-31 Therapix Biosciences Ltd. (edgar:1611746) Free cash flow: -1478000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1474000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390019008868/trpx-20181231.xml#162316 Filing: 000121390019008868 Input fundies:CapitalExpenditure: 4000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390019008868/trpx-20181231.xml#163503 Filing: 000121390019008868 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	USD 6.24 million Exact value Exact value: 6244000 USD 2017-01-01 – 2017-12-31: 6244000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2017-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: 6244000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 6244000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390019008868/trpx-20181231.xml#1211529 Filing: 000121390019008868 The citation records this snapshot. The page link may show a newer release later.	−USD 4.58 million Exact value Exact value: -4579000 USD 2017-01-01 – 2017-12-31: -4579000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2017-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -4579000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4579000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390020014990/trpx-20191231.xml#1018592 Filing: 000121390020014990 The citation records this snapshot. The page link may show a newer release later.	USD 44,000 Exact value Exact value: 44000 USD 2017-01-01 – 2017-12-31: 44000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Therapix Biosciences Ltd. · 2017-12-31 Therapix Biosciences Ltd. (edgar:1611746) Capital Expenditure: 44000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 44000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390020014990/trpx-20191231.xml#1019863 Filing: 000121390020014990 The citation records this snapshot. The page link may show a newer release later.	−USD 4.62 million Calculation and evidence -4579000 − 44000 USD Exact free cash flow: -4623000 USD 2017-01-01 – 2017-12-31: -4579000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 44000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Therapix Biosciences Ltd. · 2017-12-31 Therapix Biosciences Ltd. (edgar:1611746) Free cash flow: -4623000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4579000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390020014990/trpx-20191231.xml#1018592 Filing: 000121390020014990 Input fundies:CapitalExpenditure: 44000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390020014990/trpx-20191231.xml#1019863 Filing: 000121390020014990 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 6.53 million Exact value Exact value: 6534000 USD 2018-01-01 – 2018-12-31: 6534000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2018-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: 6534000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 6534000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390019022402/trpx-20190630.xml#172998 Filing: 000121390019022402 The citation records this snapshot. The page link may show a newer release later.	−USD 7.13 million Exact value Exact value: -7132000 USD 2018-01-01 – 2018-12-31: -7132000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2018-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -7132000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7132000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/sprcy-20201231.xml#178384 Filing: 000121390021018407 The citation records this snapshot. The page link may show a newer release later.	USD 17,000 Exact value Exact value: 17000 USD 2018-01-01 – 2018-12-31: 17000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Therapix Biosciences Ltd. · 2018-12-31 Therapix Biosciences Ltd. (edgar:1611746) Capital Expenditure: 17000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/sprcy-20201231.xml#179514 Filing: 000121390021018407 The citation records this snapshot. The page link may show a newer release later.	−USD 7.15 million Calculation and evidence -7132000 − 17000 USD Exact free cash flow: -7149000 USD 2018-01-01 – 2018-12-31: -7132000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 17000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Therapix Biosciences Ltd. · 2018-12-31 Therapix Biosciences Ltd. (edgar:1611746) Free cash flow: -7149000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7132000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/sprcy-20201231.xml#178384 Filing: 000121390021018407 Input fundies:CapitalExpenditure: 17000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/sprcy-20201231.xml#179514 Filing: 000121390021018407 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 4.69 million Exact value Exact value: 4686000 USD 2019-01-01 – 2019-12-31: 4686000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2019-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: 4686000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 4686000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390022022294/f20f2021_scisparcltd.htm#1484881 Filing: 000121390022022294 The citation records this snapshot. The page link may show a newer release later.	−USD 4.7 million Exact value Exact value: -4696000 USD 2019-01-01 – 2019-12-31: -4696000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2019-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -4696000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4696000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390022022294/f20f2021_scisparcltd.htm#1630032 Filing: 000121390022022294 The citation records this snapshot. The page link may show a newer release later.	USD 1,000 Exact value Exact value: 1000 USD 2019-01-01 – 2019-12-31: 1000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Therapix Biosciences Ltd. · 2019-12-31 Therapix Biosciences Ltd. (edgar:1611746) Capital Expenditure: 1000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390022022294/f20f2021_scisparcltd.htm#1636512 Filing: 000121390022022294 The citation records this snapshot. The page link may show a newer release later.	−USD 4.7 million Calculation and evidence -4696000 − 1000 USD Exact free cash flow: -4697000 USD 2019-01-01 – 2019-12-31: -4696000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Therapix Biosciences Ltd. · 2019-12-31 Therapix Biosciences Ltd. (edgar:1611746) Free cash flow: -4697000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4696000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390022022294/f20f2021_scisparcltd.htm#1630032 Filing: 000121390022022294 Input fundies:CapitalExpenditure: 1000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390022022294/f20f2021_scisparcltd.htm#1636512 Filing: 000121390022022294 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 3.54 million Exact value Exact value: 3535000 USD 2020-01-01 – 2020-12-31: 3535000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2020-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: 3535000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 3535000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390023034606/f20f2022_scisparc.htm#2256751 Filing: 000121390023034606 The citation records this snapshot. The page link may show a newer release later.	−USD 4.31 million Exact value Exact value: -4307000 USD 2020-01-01 – 2020-12-31: -4307000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2020-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -4307000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4307000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391-f1_scisparcltd.htm#2441262 Filing: 000121390024017526 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 5.79 million Exact value Exact value: -5789000 USD 2021-01-01 – 2021-12-31: -5789000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2021-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: -5789000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5789000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea0213908-f4_scisparc.htm#2376340 Filing: 000121390024082318 The citation records this snapshot. The page link may show a newer release later.	−USD 5.06 million Exact value Exact value: -5061000 USD 2021-01-01 – 2021-12-31: -5061000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2021-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -5061000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5061000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea0213908-f4_scisparc.htm#2574533 Filing: 000121390024082318 The citation records this snapshot. The page link may show a newer release later.	USD 35,000 Exact value Exact value: 35000 USD 2021-01-01 – 2021-12-31: 35000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Therapix Biosciences Ltd. · 2021-12-31 Therapix Biosciences Ltd. (edgar:1611746) Capital Expenditure: 35000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 35000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea0213908-f4_scisparc.htm#2582016 Filing: 000121390024082318 The citation records this snapshot. The page link may show a newer release later.	−USD 5.1 million Calculation and evidence -5061000 − 35000 USD Exact free cash flow: -5096000 USD 2021-01-01 – 2021-12-31: -5061000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 35000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Therapix Biosciences Ltd. · 2021-12-31 Therapix Biosciences Ltd. (edgar:1611746) Free cash flow: -5096000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5061000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea0213908-f4_scisparc.htm#2574533 Filing: 000121390024082318 Input fundies:CapitalExpenditure: 35000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea0213908-f4_scisparc.htm#2582016 Filing: 000121390024082318 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 2.59 million Exact value Exact value: -2592000 USD 2022-01-01 – 2022-12-31: -2592000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2022-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: -2592000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2592000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390025066626/ea0249828-6k_scisparc_htm.xml#179683 Filing: 000121390025066626 The citation records this snapshot. The page link may show a newer release later.	−USD 7.92 million Exact value Exact value: -7917000 USD 2022-01-01 – 2022-12-31: -7917000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2022-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -7917000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7917000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390025066626/ea0249828-6k_scisparc_htm.xml#199370 Filing: 000121390025066626 The citation records this snapshot. The page link may show a newer release later.	USD 8,000 Exact value Exact value: 8000 USD 2022-01-01 – 2022-12-31: 8000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Therapix Biosciences Ltd. · 2022-12-31 Therapix Biosciences Ltd. (edgar:1611746) Capital Expenditure: 8000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea0213908-f4_scisparc.htm#2581669 Filing: 000121390024082318 The citation records this snapshot. The page link may show a newer release later.	−USD 7.93 million Calculation and evidence -7917000 − 8000 USD Exact free cash flow: -7925000 USD 2022-01-01 – 2022-12-31: -7917000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 8000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Therapix Biosciences Ltd. · 2022-12-31 Therapix Biosciences Ltd. (edgar:1611746) Free cash flow: -7925000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7917000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390025066626/ea0249828-6k_scisparc_htm.xml#199370 Filing: 000121390025066626 Input fundies:CapitalExpenditure: 8000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea0213908-f4_scisparc.htm#2581669 Filing: 000121390024082318 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 5.12 million Exact value Exact value: -5122000 USD 2023-01-01 – 2023-12-31: -5122000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2023-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: -5122000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5122000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#205924 Filing: 000121390026091427 The citation records this snapshot. The page link may show a newer release later.	−USD 5.89 million Exact value Exact value: -5887000 USD 2023-01-01 – 2023-12-31: -5887000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2023-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -5887000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5887000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#358815 Filing: 000121390026091427 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 6.28 million Exact value Exact value: -6284000 USD 2024-01-01 – 2024-12-31: -6284000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2024-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: -6284000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6284000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#205573 Filing: 000121390026091427 The citation records this snapshot. The page link may show a newer release later.	−USD 5.1 million Exact value Exact value: -5104000 USD 2024-01-01 – 2024-12-31: -5104000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2024-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -5104000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5104000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#358373 Filing: 000121390026091427 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 12.18 million Exact value Exact value: -12179000 USD 2025-01-01 – 2025-12-31: -12179000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Therapix Biosciences Ltd. · 2025-12-31 Therapix Biosciences Ltd. (edgar:1611746) Net Income: -12179000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12179000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#205221 Filing: 000121390026091427 The citation records this snapshot. The page link may show a newer release later.	−USD 4.14 million Exact value Exact value: -4137000 USD 2025-01-01 – 2025-12-31: -4137000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Therapix Biosciences Ltd. · 2025-12-31 Therapix Biosciences Ltd. (edgar:1611746) Operating Cash Flow: -4137000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1611746/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4137000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1611746/000121390026091427/ea0302520-20fa1_scisparc.htm#412770 Filing: 000121390026091427 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

350 filings · 1,230 latest values · 1,230 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001611746, 1611746, SPRC, TRPX, edgar:1611746

Also known as SCISPARC LTD., SCISPARC LTD., SciSparc Ltd., SciSparc Ltd./ADR, Therapix Biosciences Ltd.

Therapix Biosciences Ltd.

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation